Minerva Neurosciences Shares Drop 58% After FDA Refusal to File Letter
marketwatch.com
news
2022-10-17 13:56:00

By Chris Wack Minerva Neurosciences Inc. shares dropped 58% to $5.68 after the company said it has received a refusal to file letter from the U.S. Food and Drug Administration regarding the company's New Drug Application for roluperidone for the treatment of negative symptoms in patients with schizophrenia. The stock closed Friday's session up 8%, and is down about 7% year to date. The biopharmaceutical company said the FDA has indicated that the company can request a Type A meeting to discuss the content of the refusal to file letter.
